Specify a stock or a cryptocurrency in the search bar to get a summary
Cardax Inc
CDXICardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii. Address: 2800 Woodlawn Drive, Honolulu, HI, United States, 96822
Analytics
WallStreet Target Price
1 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CDXI
Dividend Analytics CDXI
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CDXI
Stock Valuation CDXI
Financials CDXI
Results | 2019 | Dynamics |